What does COMMUNICATION CONSULTING MARKETING PHARMA do?

COMMUNICATION CONSULTING MARKETING PHARMA is a wholesaler in Wemmel. Private Limited, started on 2 October 2001, 1 establishment.

What is the address of COMMUNICATION CONSULTING MARKETING PHARMA?

The registered office of COMMUNICATION CONSULTING MARKETING PHARMA is located at Brabants Dal 15, 1780 Wemmel.

Is COMMUNICATION CONSULTING MARKETING PHARMA still active?

Yes. According to the CBE (31 October 2026) COMMUNICATION CONSULTING MARKETING PHARMA is active, legal situation “Normale toestand”, started on 2 October 2001.

Is COMMUNICATION CONSULTING MARKETING PHARMA registered on Peppol?

Yes, COMMUNICATION CONSULTING MARKETING PHARMA is registered on the Peppol network with ID 0208:0475754613.

What is the enterprise number of COMMUNICATION CONSULTING MARKETING PHARMA?

The enterprise number of COMMUNICATION CONSULTING MARKETING PHARMA is BE0475754613.

When was COMMUNICATION CONSULTING MARKETING PHARMA founded?

COMMUNICATION CONSULTING MARKETING PHARMA was founded on 2 October 2001.

Who are the directors of COMMUNICATION CONSULTING MARKETING PHARMA?

According to the 2025 annual accounts, the directors of COMMUNICATION CONSULTING MARKETING PHARMA are: Johan Smitz.

Is COMMUNICATION CONSULTING MARKETING PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 October 2001; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did COMMUNICATION CONSULTING MARKETING PHARMA make in 2025?

COMMUNICATION CONSULTING MARKETING PHARMA posted a profit after taxes of € 41,600 in financial year 2025.

What is the revenue of COMMUNICATION CONSULTING MARKETING PHARMA?

As a small company, COMMUNICATION CONSULTING MARKETING PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 71,186.

COMMUNICATION CONSULTING MARKETING PHARMA (Private Limited)

Dossier COMMUNICATION CONSULTING MARKETING PHARMA, printed on 31 October 2026 from databakkes.be/en/0475754613/communication-consulting-marketing-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

COMMUNICATION CONSULTING MARKETING PHARMA from Wemmel, company number BE0475754613, closed financial year 2025 with a result of € 41,600 after tax. For that financial year COMMUNICATION CONSULTING MARKETING PHARMA recorded a gross margin of € 71,186 and equity of € 262,283. Compared with financial year 2024, the result moved from € 48,190 to € 41,600. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 262,283

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 41,600

▼ 14% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 89,313

▲ 75% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 249,883.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 23,016

▼ 31% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 986

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,541

▼ 76% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 136,236 Gross margin 2022: € 136,236 First fiscal year in the series	€ 87,565 Gross margin 2023: € 87,565 ▼ 36% vs 2022 (€ 136,236) Unfavourable step	€ 77,730 Gross margin 2024: € 77,730 ▼ 11% vs 2023 (€ 87,565) Unfavourable step	€ 71,186 Gross margin 2025: € 71,186 ▼ 8% vs 2024 (€ 77,730) Unfavourable step	▼ 8%
Profit after taxes	€ 82,844 Profit after taxes 2022: € 82,844 First fiscal year in the series	€ 50,317 Profit after taxes 2023: € 50,317 ▼ 39% vs 2022 (€ 82,844) Unfavourable step	€ 48,190 Profit after taxes 2024: € 48,190 ▼ 4% vs 2023 (€ 50,317) Unfavourable step	€ 41,600 Profit after taxes 2025: € 41,600 ▼ 14% vs 2024 (€ 48,190) Unfavourable step	▼ 14%
Equity	€ 122,176 Equity 2022: € 122,176 First fiscal year in the series	€ 172,493 Equity 2023: € 172,493 ▲ 41% vs 2022 (€ 122,176) Favourable step	€ 220,683 Equity 2024: € 220,683 ▲ 28% vs 2023 (€ 172,493) Favourable step	€ 262,283 Equity 2025: € 262,283 ▲ 19% vs 2024 (€ 220,683) Favourable step	▲ 19%
Total debts	€ 50,591 Total debts 2022: € 50,591 First fiscal year in the series	€ 55,630 Total debts 2023: € 55,630 ▲ 10% vs 2022 (€ 50,591) Unfavourable step	€ 14,522 Total debts 2024: € 14,522 ▼ 74% vs 2023 (€ 55,630) Favourable step	€ 4,527 Total debts 2025: € 4,527 ▼ 69% vs 2024 (€ 14,522) Favourable step	▼ 69%
Cash	€ 80,829 Cash 2022: € 80,829 First fiscal year in the series	€ 107,742 Cash 2023: € 107,742 ▲ 33% vs 2022 (€ 80,829) Favourable step	€ 51,125 Cash 2024: € 51,125 ▼ 53% vs 2023 (€ 107,742) Unfavourable step	€ 89,313 Cash 2025: € 89,313 ▲ 75% vs 2024 (€ 51,125) Favourable step	▲ 75%
Retained profit	€ 109,776 Retained profit 2022: € 109,776 First fiscal year in the series	€ 160,093 Retained profit 2023: € 160,093 ▲ 46% vs 2022 (€ 109,776) Favourable step	€ 208,283 Retained profit 2024: € 208,283 ▲ 30% vs 2023 (€ 160,093) Favourable step	€ 249,883 Retained profit 2025: € 249,883 ▲ 20% vs 2024 (€ 208,283) Favourable step	▲ 20%
Balance sheet total	€ 172,767 Balance sheet total 2022: € 172,767 First fiscal year in the series	€ 228,123 Balance sheet total 2023: € 228,123 ▲ 32% vs 2022 (€ 172,767) Unchanged	€ 235,205 Balance sheet total 2024: € 235,205 ▲ 3% vs 2023 (€ 228,123) Unchanged	€ 266,810 Balance sheet total 2025: € 266,810 ▲ 13% vs 2024 (€ 235,205) Unchanged	▲ 13%

Key figures of COMMUNICATION CONSULTING MARKETING PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to COMMUNICATION CONSULTING MARKETING PHARMA?

What happened at COMMUNICATION CONSULTING MARKETING PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 41,600 (▼ 14% vs 2024). Source: NBB ↗
2014 Johan Smitz became a director. NBB
Dec 6, 2001 New establishment in Wemmel. KBO
Oct 2, 2001 Start of the company according to the CBE. KBO

In short

From € 82,844 profit in 2022 to € 41,600 profit in 2025.

Paid € 108,560 in corporate taxes since 2022.

Best year ever: 2022, with € 82,844 profit.

Original PDFs at the National Bank ↗

Management

Johan Smitz

COMMUNICATION CONSULTING MARKETING PHARMA

Behind COMMUNICATION CONSULTING MARKETING PHARMA is Johan Smitz.

Directors

According to the 2025 annual accounts

Johan Smitz

Director

since 2014

Establishments

Establishment units

Physical locations of this company

Registered office

Brabants Dal 15

1780 Wemmel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Smitz-Otsuki

€ 117,630 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0475.754.613

VAT number

BE 0475.754.613

Registered office

Brabants Dal 15, 1780 Wemmel

Names & denominations

COMMUNICATION CONSULTING MARKETING PHARMA · C.C.M. PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 October 2001

Peppol

Active · Active since 15 Jan 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Markt- en opinieonderzoek

Marktonderzoekbureaus

View on CBE Public ↗ Annual accounts (NBB) ↗